Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Switzerland says U.S. announcement on vaccine patent waiver leaves questions

05/06/2021 | 12:17pm EDT

ZURICH, May 6 (Reuters) - The Swiss government said on Thursday a U.S. announcement to support waiving intellectual property rights for COVID-19 vaccines was a significant announcement but left many questions unanswered.

"This is an important announcement by the U.S., but many questions remain unanswered about the specific solutions it is considering in this context," the State Secretariat for Economic Affairs (SECO) said in an emailed statement.

SECO said Switzerland was still convinced that waiving intellectual property rights in the context of the pandemic could not guarantee fair, affordable and rapid access to vaccines, drugs and diagnostic products against COVID-19.

It said Switzerland would examine this new U.S. request and its consequences on the Swiss position, with the United States itself and within the World Trade Organisation. (Reporting by Silke Koltrowitz; Editing by Andrew Cawthorne)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
LONZA GROUP AG -1.14% 658 Delayed Quote.17.02%
NOVARTIS AG 0.88% 85.93 Delayed Quote.1.83%
ROCHE HOLDING AG 0.37% 348.4 Delayed Quote.12.33%
All news about NOVARTIS AG
03:55pCureVac may let contractors make rival vaccines if own shot fails -CEO
RE
12:14pCureVac may let contractors make rival vaccines if own shot fails - CEO
RE
06:39aNOVARTIS AGá : Deutsche Bank keeps its Buy rating
MD
12:31aEMEA MORNING BRIEFINGá : Fed's Surprise Hawkish -2-
DJ
06/16NOVARTISá : Wins US FDA Breakthrough Therapy Designation For Prostate Cancer Tre..
MT
06/16CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy
RE
06/16NOVARTISá : prostate cancer drug receives U.S. FDA breakthrough designation
RE
06/16NOVARTISá : AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains A..
MT
06/15NOVARTIS AGá : Gets a Buy rating from Berenberg
MD
06/14NOVARTISá : investigational oral therapy iptacopan (LNP023) shows benefit as mon..
AQ
More news
Financials (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,9x
Yield 2021 3,50%
Capitalization 212 B 210 B -
EV / Sales 2021 4,55x
EV / Sales 2022 4,27x
Nbr of Employees 110 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 106,54 $
Last Close Price 93,71 $
Spread / Highest target 58,9%
Spread / Average Target 13,7%
Spread / Lowest Target -6,56%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG1.83%212 691
JOHNSON & JOHNSON4.48%433 009
ROCHE HOLDING AG12.33%333 736
PFIZER, INC.6.76%219 989
ABBVIE INC.7.82%204 052
ELI LILLY AND COMPANY30.75%200 676